Review



rrid goat anti mouse il 1ra biotinylated r d systems baf480 ab 2249043 streptavidin conjugated af488  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems rrid goat anti mouse il 1ra biotinylated r d systems baf480 ab 2249043 streptavidin conjugated af488
    Rrid Goat Anti Mouse Il 1ra Biotinylated R D Systems Baf480 Ab 2249043 Streptavidin Conjugated Af488, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Biotinylated+Antibody/pm41116045-366-32-37
    Average 93 stars, based on 13 article reviews
    rrid goat anti mouse il 1ra biotinylated r d systems baf480 ab 2249043 streptavidin conjugated af488 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: Yersinia pestis Activates Both IL-1β and IL-1 Receptor Antagonist to Modulate Lung Inflammation during Pneumonic Plague
    Article Snippet: Mouse IL-1RA/IL-1F3 antibody and Mouse IL-18BP antibody were commercially obtained (R&D Systems) and resuspended in 1X PBS.



    Similar Products

    94
    Bio-Techne corporation il1r ab
    Il1r Ab, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Antibody/pm38788899-275-4-7
    Average 94 stars, based on 1 article reviews
    il1r ab - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    R&D Systems rrid goat anti mouse il 1ra biotinylated r d systems baf480 ab 2249043 streptavidin conjugated af488
    Rrid Goat Anti Mouse Il 1ra Biotinylated R D Systems Baf480 Ab 2249043 Streptavidin Conjugated Af488, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Biotinylated+Antibody/pm41116045-366-32-37
    Average 93 stars, based on 1 article reviews
    rrid goat anti mouse il 1ra biotinylated r d systems baf480 ab 2249043 streptavidin conjugated af488 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Proteintech mouse il 1ra il 1f3 elisa kit
    Mouse Il 1ra Il 1f3 Elisa Kit, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/IL-1RA+Antibody/pm40854504-140-41-46
    Average 93 stars, based on 1 article reviews
    mouse il 1ra il 1f3 elisa kit - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    92
    R&D Systems mouse anti human il 1ra antibodies
    Fig. 1. Effect of <t>anakinra</t> on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
    Mouse Anti Human Il 1ra Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Human+IL-1ra%2FIL-1F3+Antibody/pm39121163-258-10-16
    Average 92 stars, based on 1 article reviews
    mouse anti human il 1ra antibodies - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    91
    R&D Systems il1 ra 15 neutralizing antibody
    Fig. 1. Effect of <t>anakinra</t> on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
    Il1 Ra 15 Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Antibody/ppr0774890-220-23-28
    Average 91 stars, based on 1 article reviews
    il1 ra 15 neutralizing antibody - by Bioz Stars, 2026-09
    91/100 stars
      Buy from Supplier

    93
    R&D Systems anti mouse il1ra
    Fig. 1. Effect of <t>anakinra</t> on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
    Anti Mouse Il1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Biotinylated+Antibody/pm37478856-751-7-9
    Average 93 stars, based on 1 article reviews
    anti mouse il1ra - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    R&D Systems il 1ra
    Fig. 1. Effect of <t>anakinra</t> on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
    Il 1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Antibody/pm33739383-31-3-8
    Average 93 stars, based on 1 article reviews
    il 1ra - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    R&D Systems polyclonal goat anti mouse il1ra
    Fig. 1. Effect of <t>anakinra</t> on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
    Polyclonal Goat Anti Mouse Il1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+il+1ra+il+1f3+antibody/Mouse+IL-1ra%2FIL-1F3+Antibody/pm31932497-167-16-28
    Average 93 stars, based on 1 article reviews
    polyclonal goat anti mouse il1ra - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 1. Effect of anakinra on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.

    doi: 10.1073/pnas.2405644121

    Figure Lengend Snippet: Fig. 1. Effect of anakinra on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

    Article Snippet: They were then stained overnight at 4 °C with primary mouse anti- human IL- 1Ra antibodies (R&D systems, catalog no. MAB280) (1:500 in 5% goat serum (Gibco, Cat. 16210072) in PBS).

    Techniques: In Vitro, Cell Culture, Western Blot, Control, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Staining

    Fig. 2. Localization of anakinra and effect on oxidative stress in CLL cells. (A) IL-1α (1.24 ± 1.006) (N = 3 0), IL-1β (0.997 ± 0.158) (N = 34), and IL-1Ra (98.475±28.467) (N = 28) were measured in supernatants of CLL cells after 48 h. Patient numbers differ because samples were assayed in different batch- es. Each circle is the result for an individ- ual sample. Averages and SE are shown. (B) CLL cells were stimulated with IL-1β or resiquimod (S) (N = 3). Phospho-p38 was quantified after 30 min by immunoblotting and densitometry with β-actin as a loading control. A representative blot is shown. In- dividual patient samples in the graph are indicated by dots. Averages and SE are Con: 0.33 ± 0.201, IL-1β: 0.264 ± 0.003, and S: 3.497 ± 0.458. (C) CLL cells precultured with or without neutralizing IL-1 receptor antibodies for 2 h before adding IL-2 and resiquimod (2S) in the presence or absence of anakinra (K) for 48 h were analyzed by confocal microscopy as described in the materials and methods. Representative images are shown, with similar results ob- tained with 5 different patient samples. (D) IL-1Ra-staining quantified for 5 images per treatment per patient sample is shown in the summary graph, with each dot repre- senting a different image. Averages and SE of mean fluorescence intensities (MFIs) are Con: 91.407 ± 3.589, 2S:169.692 ± 38.945, 2S+K:1263.622 ± 145.864, and 2S+K + anti- IL-1RI: 1741.328 ± 208.275. (E) CLL cells (N = 7) were cultured with or without anak- inra (K) for 48 h and stained with DCFH to measure intracellular ROS levels. Rep- resentative histograms (Left) and MFIs of DCFH staining for individual patient samples (Right) are shown. Statistical significance was determined using Student’s t tests. *P < 0.05; **P < 0.01; ns, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.

    doi: 10.1073/pnas.2405644121

    Figure Lengend Snippet: Fig. 2. Localization of anakinra and effect on oxidative stress in CLL cells. (A) IL-1α (1.24 ± 1.006) (N = 3 0), IL-1β (0.997 ± 0.158) (N = 34), and IL-1Ra (98.475±28.467) (N = 28) were measured in supernatants of CLL cells after 48 h. Patient numbers differ because samples were assayed in different batch- es. Each circle is the result for an individ- ual sample. Averages and SE are shown. (B) CLL cells were stimulated with IL-1β or resiquimod (S) (N = 3). Phospho-p38 was quantified after 30 min by immunoblotting and densitometry with β-actin as a loading control. A representative blot is shown. In- dividual patient samples in the graph are indicated by dots. Averages and SE are Con: 0.33 ± 0.201, IL-1β: 0.264 ± 0.003, and S: 3.497 ± 0.458. (C) CLL cells precultured with or without neutralizing IL-1 receptor antibodies for 2 h before adding IL-2 and resiquimod (2S) in the presence or absence of anakinra (K) for 48 h were analyzed by confocal microscopy as described in the materials and methods. Representative images are shown, with similar results ob- tained with 5 different patient samples. (D) IL-1Ra-staining quantified for 5 images per treatment per patient sample is shown in the summary graph, with each dot repre- senting a different image. Averages and SE of mean fluorescence intensities (MFIs) are Con: 91.407 ± 3.589, 2S:169.692 ± 38.945, 2S+K:1263.622 ± 145.864, and 2S+K + anti- IL-1RI: 1741.328 ± 208.275. (E) CLL cells (N = 7) were cultured with or without anak- inra (K) for 48 h and stained with DCFH to measure intracellular ROS levels. Rep- resentative histograms (Left) and MFIs of DCFH staining for individual patient samples (Right) are shown. Statistical significance was determined using Student’s t tests. *P < 0.05; **P < 0.01; ns, not significant.

    Article Snippet: They were then stained overnight at 4 °C with primary mouse anti- human IL- 1Ra antibodies (R&D systems, catalog no. MAB280) (1:500 in 5% goat serum (Gibco, Cat. 16210072) in PBS).

    Techniques: Western Blot, Control, Confocal Microscopy, Staining, Fluorescence, Cell Culture

    Fig. 4. Effect of anakinra on IFN responses in CLL cells in vivo and in vitro. (A) DEGs in circulating CLL cells from six patients at C1D1 and C1D14 were compared by GSEA. The enrichment plot indicates that anakinra up-regulated IFN-stimulated gene expression. (B) Phospho-STAT2 was measured in protein extracts from cryopreserved CLL cells obtained at C1D1 and C1D14 (N = 5) by immunoblotting and densitometry using β-actin as a loading control. (C and D) CLL cells were cultured with and without anakinra (K). Phospho-STAT2 (exposure time 1 min) was measured after 24 h (N = 11) (C). CXCL10 was measured by the ELISA after 48 h (N = 10) (D). (E–G) CLL cells were cultured with or without anakinra for 24 h and then stimulated with IFNβ. E. OASL transcripts were measured after 4 h (N = 11). Averages and SE are Con: 0.219 ± 0.076, K: 0.386 ± 0.117, IFNβ: 7.41 ± 1.617, K + IFNβ: 10.115 ± 2.041. (F) Phospho-STAT1 and -STAT2 (exposure time 5 s) were measured after 30 min (N = 7). Averages and SE are Con: 0.09 ± 0.032, IFNβ: 1.271 ± 0.197, K: 0.098 ± 0.035, K + IFNβ: 2.348 ± 0.244 for P-STAT1 and Con: 0.063 ± 0.024, IFNβ: 1.161 ± 0.254, K: 0.058 ± 0.018, K + IFNβ: 2.395 ± 0.456 for P-STAT2. (G) LAG3 was measured after 24 h. A representative example is shown in Supplementary Fig. S6. Percentages of LAG3+ cells in each condition normalized to the result for IFN-treated cells without anakinra are plotted in the summary graph. Examples of immunoblots are shown, and each line or dot in the graphs represents results for an individual patient. The means and SEMs normalized to IFNβ are Con: 0.251 ± 0.045, K: 0.327 ± 0.117, IFNβ: 1 ± 0, and IFNβ+K: 1.183 ± 0.045. (H and I) CLL cells were cultured in RPMI-1640 in the absence (H) or presence (I) of IFNβ with or without K, anifrolumab (ANI), or both (N = 14). Live (DAPI−) cells were measured after 4 d. Examples of contour plots are shown, with numbers indicating % DAPI− cells. Each dot in the summary graphs represents an individual patient. (H) Averages and SE of % live cells are Con: 29.666 ± 1.591, K: 38.369 ± 2.546, ANI: 30.65 ± 1.733, and K + ANI: 31.428 ± 2.104. (I) Averages and SE are Con: 60.839 ± 5.642, K + IFNβ: 78.786 ± 4.617, K + IFNβ+ANI: 51.804 ± 6.57. Statistical analysis was performed with Student’s t tests and one-way ANOVAs. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, not significant.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.

    doi: 10.1073/pnas.2405644121

    Figure Lengend Snippet: Fig. 4. Effect of anakinra on IFN responses in CLL cells in vivo and in vitro. (A) DEGs in circulating CLL cells from six patients at C1D1 and C1D14 were compared by GSEA. The enrichment plot indicates that anakinra up-regulated IFN-stimulated gene expression. (B) Phospho-STAT2 was measured in protein extracts from cryopreserved CLL cells obtained at C1D1 and C1D14 (N = 5) by immunoblotting and densitometry using β-actin as a loading control. (C and D) CLL cells were cultured with and without anakinra (K). Phospho-STAT2 (exposure time 1 min) was measured after 24 h (N = 11) (C). CXCL10 was measured by the ELISA after 48 h (N = 10) (D). (E–G) CLL cells were cultured with or without anakinra for 24 h and then stimulated with IFNβ. E. OASL transcripts were measured after 4 h (N = 11). Averages and SE are Con: 0.219 ± 0.076, K: 0.386 ± 0.117, IFNβ: 7.41 ± 1.617, K + IFNβ: 10.115 ± 2.041. (F) Phospho-STAT1 and -STAT2 (exposure time 5 s) were measured after 30 min (N = 7). Averages and SE are Con: 0.09 ± 0.032, IFNβ: 1.271 ± 0.197, K: 0.098 ± 0.035, K + IFNβ: 2.348 ± 0.244 for P-STAT1 and Con: 0.063 ± 0.024, IFNβ: 1.161 ± 0.254, K: 0.058 ± 0.018, K + IFNβ: 2.395 ± 0.456 for P-STAT2. (G) LAG3 was measured after 24 h. A representative example is shown in Supplementary Fig. S6. Percentages of LAG3+ cells in each condition normalized to the result for IFN-treated cells without anakinra are plotted in the summary graph. Examples of immunoblots are shown, and each line or dot in the graphs represents results for an individual patient. The means and SEMs normalized to IFNβ are Con: 0.251 ± 0.045, K: 0.327 ± 0.117, IFNβ: 1 ± 0, and IFNβ+K: 1.183 ± 0.045. (H and I) CLL cells were cultured in RPMI-1640 in the absence (H) or presence (I) of IFNβ with or without K, anifrolumab (ANI), or both (N = 14). Live (DAPI−) cells were measured after 4 d. Examples of contour plots are shown, with numbers indicating % DAPI− cells. Each dot in the summary graphs represents an individual patient. (H) Averages and SE of % live cells are Con: 29.666 ± 1.591, K: 38.369 ± 2.546, ANI: 30.65 ± 1.733, and K + ANI: 31.428 ± 2.104. (I) Averages and SE are Con: 60.839 ± 5.642, K + IFNβ: 78.786 ± 4.617, K + IFNβ+ANI: 51.804 ± 6.57. Statistical analysis was performed with Student’s t tests and one-way ANOVAs. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, not significant.

    Article Snippet: They were then stained overnight at 4 °C with primary mouse anti- human IL- 1Ra antibodies (R&D systems, catalog no. MAB280) (1:500 in 5% goat serum (Gibco, Cat. 16210072) in PBS).

    Techniques: In Vivo, In Vitro, Gene Expression, Western Blot, Control, Cell Culture, Enzyme-linked Immunosorbent Assay